AKBA
Akebia Ther
NASDAQ: AKBA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.36
-4.23% today
Updated 2026-04-29
Market cap
$364.82M
P/E ratio
—
P/S ratio
1.55x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$1 – $4
Volume
2.7M
Akebia Ther (AKBA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-2.26%
Operating margin
-10.50%
ROE
-553.00%
ROA
5.44%
Debt/equity
1.26x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-8.20M | — | — | — |
| 2013 | — | $-13.17M | — | — | — |
| 2014 | $700233.00 | $-37.03M | -3,322.18% | -5,418.20% | -5,288.81% |
| 2015 | $0.00 | $-60.72M | — | — | — |
| 2016 | $1.53M | $-135.75M | -7,443.00% | -8,889.90% | -8,843.45% |
| 2017 | $177.98M | $-76.91M | 99.65% | -44.90% | -43.21% |
| 2018 | $207.74M | $-171.90M | 96.30% | -85.75% | -82.75% |
| 2019 | $335.00M | $-279.66M | 56.62% | -85.46% | -83.48% |
| 2020 | $295.31M | $-349.87M | -0.20% | -127.47% | -118.48% |
| 2021 | $213.58M | $-244.87M | 28.18% | -124.23% | -114.65% |
| 2022 | $292.48M | $-94.23M | 92.31% | -27.62% | -32.22% |
| 2023 | $194.62M | $-51.92M | 61.90% | -23.77% | -26.68% |
| 2024 | $160.18M | $-69.41M | 60.56% | -31.51% | -43.33% |
| 2025 | $236.20M | $-5.34M | 83.29% | 9.95% | -2.26% |